EDIT Research and Charts

EDIT - Editas Medicine Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2025-02-03 (Delayed quote data 2025-05-09)

Last 1.45	Change ⇑ +0.06 (+4.32%)	Volume 2,653,671
	Open 1.42	High 1.53	Low 1.41

8EMA (Daily) 1.45	40EMA (Daily) 1.42	50EMA (Daily) 1.44	STO (Daily) 37.752	MACD Hist (Daily) -0.022
8EMA (Weekly) 1.449	40EMA (Weekly) 2.48	50EMA (Weekly) 2.96	STO (Weekly) 22.678	MACD Hist (Weekly) 0.253


Company Profile
Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company's only operating segment being developing and commercializing genome editing technology.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.